Clinical trials: Obstructive Lung Disease
Asthma
4 Week 2 Way Crossover Double Blind Treatment Phase With Combivent CFC Versus Albuterol Followed by a 4 Week Open Label Combivent Respimat When All Drugs Are Used for Symptom Relief as Needed in Pts With Moderate to Severe Asthma
The primary goal of this trial is to compare the efficacy and safety of COMBIVENT CFC MDI with albuterol HFA MDI, the current standard reliever medication in asthma.
- Trial name
- NCT00818454
- Testing
- Combivent CFC MDI, Albuterol HFA MDI, Respimat Combivent
- Where
- 41 sites in United States
- Volunteers
- 226 people
- Sponsor
- Boehringer Ingelheim
Hypercapnic Respiratory Failure, Chronic Obstructive Pulmonary Disease
Clinical Stabilization of Hypercapnia: NIPPV v HVNI
This study will evaluate the ability of High Velocity Nasal Insufflation [HVNI] to effect ventilation and related physiologic responses in hypercapnic patients when compared to noninvasive positive pressure ventilation [NIPPV].
- Conditions
- Hypercapnic Respiratory Failure, Chronic Obstructive Pulmonary Disease, Dyspnea, Hypercapnic Acidosis
- Trial name
- HYPERACT (NCT04709562)
- Testing
- High Velocity Nasal Insufflation (HVNI), Noninvasive Positive Pressure Ventilation (NIPPV)
- Where
- 7 sites in United States
- Volunteers
- 68 people, healthy volunteers welcome
- Sponsor
- Vapotherm, Inc.
Asthma
Post-marketing Safety Monitoring Program of Fluticasone Propionate (FP) in Chinese Subjects With Asthma Aged 1 to <4 Years
For the prophylactic treatment of asthma, FP inhaled aerosol (Flixotide ®) administered via a pressurized metered-dose inhaler (pMDI) was approved in China in adults, adolescents older than 16 years of age and children aged 4 to…
- Trial name
- NCT03273946
- Testing
- Fluticasone propionate
- Where
- 4 sites in China
- Volunteers
- 158 people
- Sponsor
- GlaxoSmithKline
Asthma
A Study to Assess the Efficacy and Safety of Budesonide/Albuterol Metered Dose Inhaler (BDA MDI/PT027) Used 4 Times Daily in Adults and Children 4 Years of Age or Older With Asthma
This is a randomized, double-blind, placebo-controlled, multicenter, parallel group study to compare 2 dose levels of budesonide/albuterol BDA MDI (PT027) to its components budesonide BD MDI (PT008) and albuterol AS MDI (PT007)…
- Trial name
- DENALI (NCT03847896)
- Testing
- Budesonide/albuterol sulfate metered dose inhaler / BDA MDI 160/180 μg (high dose), Budesonide/albuterol sulfate metered dose inhaler / BDA MDI 80/180 μg (low dose), Budesonide metered dose inhaler / BD MDI 160 µg
- Where
- 129 sites in United States, Argentina and 5 more
- Volunteers
- 1,001 people
- Sponsor
- Bond Avillion 2 Development LP
Pulmonary Hypertension, Chronic Obstructive Pulmonary Disease (COPD)
Tadalafil for Pulmonary Hypertension Due to Chronic Lung Disease
The functional, social, and economic burden of chronic obstructive lung disease (COPD) on the healthcare system is extraordinary.
- Trial name
- TADA-PHILD (NCT01862536)
- Testing
- Tadalafil
- Where
- 5 sites in United States
- Volunteers
- 44 people
- Sponsor
- VA Office of Research and Development
Asthma
A Study of Itolizumab (EQ001) to Evaluate the Safety, Tolerability, PK, PD, and Clinical Activity in Uncontrolled Asthma
This is a multi-center study to evaluate the safety, tolerability, PK, PD, and clinical activity of itolizumab (EQ001) in subjects with moderate-to-severe asthma.
- Trial name
- EQUIP (NCT04007198)
- Testing
- EQ001
- Where
- 13 sites in Australia, New Zealand
- Volunteers
- 18 people
- Sponsor
- Biocon Limited
Chronic Obstructive Pulmonary Disease
Efficacy and Safety Study of Indacaterol Maleate/Glycopyrronium Bromide in Chronic Obstructive Pulmonary Disease (COPD) Patients.
The purpose of this study is to demonstrate that the efficacy of the combination product QVA149 is similar to the efficacy of the combination product umeclidinium/vilanterol on a pre-specified endpoint of FEV1 AUC0-24h while…
- Trial name
- NCT02487498
- Testing
- QVA149, Umeclidinium/vilanterol
- Where
- 53 sites in United States
- Volunteers
- 355 people
- Sponsor
- Novartis Pharmaceuticals
Asthma
PF-04191834 Single Dose Bronchodilatory Study In Asthma.
Study to determine the bronchodilatory effects of PF-04191834 compared with zileuton in patients with asthma
- Trial name
- NCT00723021
- Testing
- PF-04191834, zileuton
- Where
- 4 sites in United States
- Volunteers
- 15 people
- Sponsor
- Pfizer
Chronic Obstructive Pulmonary Disease
Osteopathy in Chronic Obstructive Pulmonary Disease (COPD) Rehabilitation Trial
The purpose of this trial is to verify if an osteopathic treatment added to usual pulmonary rehabilitation trial is able to improve the walking ability of COPD patients and if there is any influence on lung functionality.
- Trial name
- NCT00637299
- Testing
- Active osteopathic treatment (OMT+PR): Active Comparator
- Where
- Italy
- Volunteers
- 20 people
- Sponsor
- Fondazione Salvatore Maugeri
Pulmonary Disease, Chronic Obstructive
A 52-Week, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Safety and Tolerability of GSK573719/GW642444 and GSK573719 in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
The purpose of this 52-week study is to evaluate the long-term safety (in terms of adverse events, COPD exacerbations, laboratory, ECG, and Holter findings, vital signs, use of rescue medication and lung function) of…
- Trial name
- COPD nDPI (NCT01316887)
- Testing
- 125/25 mcg once-daily GSK573719/GW642444, 125mcg once-daily GSK573719
- Where
- 54 sites in United States, Chile and 4 more
- Volunteers
- 563 people
- Sponsor
- GlaxoSmithKline
Asthma
Efficacy and Safety of BI 655066/ABBV-066 (Risankizumab) in Patients With Severe Persistent Asthma
The objectives of this trial are primarily to evaluate the efficacy and safety of BI 655066/ABBV-066 (risankizumab) as compared to placebo over a 24-week treatment period in severe asthma patients.
- Trial name
- NCT02443298
- Testing
- risankizumab
- Where
- 65 sites in United States, Belgium and 8 more
- Volunteers
- 214 people
- Sponsor
- AbbVie
Asthma
A Study to Determine Long-term Safety of Mepolizumab in Asthmatic Subjects
This is a multi-centre, open-label long-term safety study of 100 milligram (mg) mepolizumab administered subcutaneously (SC) every 4 weeks for 12 months in addition to standard of care in subjects who have severe, refractory…
- Trial name
- NCT01842607
- Testing
- Mepolizumab
- Where
- 137 sites in United States, Argentina and 17 more
- Volunteers
- 651 people
- Sponsor
- GlaxoSmithKline
Asthma
School-based Asthma Care for Teens (SB-ACT)
The goal of this study is to evaluate the widespread implementation of a developmentally appropriate preventive asthma care intervention for urban teens.
- Trial name
- SB-ACT (NCT02206061)
- Testing
- School-Based Asthma Care for Teens (SB-ACT), Directly Observed Therapy, Asthma Education
- Where
- United States
- Volunteers
- 430 people
- Sponsor
- University of Rochester
Chronic Obstructive Pulmonary Disease
Reliability, Sensitivity and Validity of the 6 Minute Step Test in Chronic Obstructive Pulmonary Disease (COPD) Patients
Chronic Obstructive Pulmonary Disease (COPD) leads to a reduction in exercise capacity that affects the quality of life and increases mortality of these patients.
- Trial name
- NCT01298661
- Testing
- Six-minute Step Test
- Where
- Brazil
- Volunteers
- 91 people, healthy volunteers welcome
- Sponsor
- Universidade Federal de Sao Carlos
Pulmonary Disease, Chronic Obstructive
24-week Trial Comparing GSK573719/GW642444 With GSK573719 and With Tiotropium in Chronic Obstructive Pulmonary Disease
This is a Phase III multicenter, randomized, double-blind, double-dummy, parallel-group study to evaluate the efficacy and safety of two doses of GSK573719/GW642444 Inhalation Powder, GSK573719 Inhalation Powder via a Novel Dry…
- Trial name
- NCT01316913
- Testing
- GSK573719/GW642444 125/25, GSK573719/GW642444 62.5/25, GSK573719
- Where
- 100 sites in United States, Argentina and 8 more
- Volunteers
- 872 people
- Sponsor
- GlaxoSmithKline
Asthma
A Study to Compare the Efficacy and Safety of Different Dosings of Olodaterol Administered With the Respimat® Inhaler in Patients With Moderate to Severe Asthma
This study will compare efficacy and safety of different regimens of olodaterol administration in asthma (once daily, twice daily) with placebo in a complete cross-over design each within one of the two daily dose groups (medium…
- Trial name
- NCT01311661
- Testing
- Olodaterol low daily dose twice daily, Olodaterol medium daily dose twice daily
- Where
- 36 sites in United States, Austria and 4 more
- Volunteers
- 206 people
- Sponsor
- Boehringer Ingelheim
Asthma
A Multifaceted Prompting Intervention for Urban Children With Asthma
The overall goal of this project is to evaluate whether a multifaceted prompting intervention, administered in the urban primary care office setting, reduces morbidity among urban children with asthma.
- Trial name
- PAIR-UP (NCT01105754)
- Testing
- Multifaceted Prompting Intervention MPI
- Where
- United States
- Volunteers
- 638 people
- Sponsor
- University of Rochester
Diabetes Mellitus, Asthma
Evaluation of VLER-Indiana Health Information Exchange Demonstration Project
Three out of four Veterans receive a portion of their care from non-VA providers. On April 9, 2009, President Barack Obama directed the Department of Veterans Affairs and the Department of Defense to create the Virtual Lifetime…
- Conditions
- Diabetes Mellitus, Asthma, Cardiovascular Diseases, Heart Failure
- Trial name
- VLER-IHIE (NCT01446705)
- Testing
- Active Health Information Exchange, Non-Active Health Information exchange
- Where
- United States
- Volunteers
- 57,073 people
- Sponsor
- VA Office of Research and Development
Asthma, Cough
A Cross-sectional Study to Measure Cough in Severe Asthma
This study aims to characterise cough in severe asthma through an observational cross-sectional analysis of patients stratified by inflammatory biomarker profile using a number of subjective and objective cough measurement tools.
- Trial name
- CISA (NCT03999203)
- Testing
- Citric acid, Leicester Cough monitor, fractional exhaled nitric oxide testing (FeNO)
- Where
- United Kingdom
- Volunteers
- 61 people
- Sponsor
- Queen's University, Belfast
Dermatitis, Chronic
Ethanol-Free Clobetasol Propionate Foam 0.05% (Olux-E Foam) vs Vehicle Foam in the Treatment of Chronic Hand Dermatitis.
The purpose of this study is to determine how clobetasol proprionate foam works against a placebo foam in the treatment of hand dermatitis.
- Trial name
- NCT01323673
- Testing
- clobetasol propionate 0.05%
- Where
- 10 sites in United States
- Volunteers
- 125 people
- Sponsor
- Stiefel, a GSK Company
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.